statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MiNK Therapeutics (NASDAQ:INKT  Free Report) had its target price reduced by HC Wainwright from $10.00 to $9.00 in a report released on Thursday morning, Benzinga reports. They currently have...

HC Wainwright Lowers MiNK Therapeutics (NASDAQ:INKT) Price Target to $9.00

Q4 2023 Mink Therapeutics Inc Earnings Call Transcript

Launched and enrolling Phase 2 trial of allo-iNKTs with botensilimab/balstilimab and chemotherapy in second-line gastroesophageal cancers Announced collaboration with Immunoscape for development...

MiNK Reports Fourth Quarter and Year-End 2023 Results

Earnings Outlook For MiNK Therapeutics

NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of...

MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

MiNK Therapeutics announces preclinical data from MiNK-215

MiNK-215 Eradicated Tumor Cells in Human Organoid MSS Colorectal Cancer Liver Metastases ModelNEW YORK, March 06, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage...

MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024

MiNK Therapeutics, Inc. (NASDAQ:INKT  Get Free Report) was the recipient of a significant drop in short interest in the month of February. As of February 15th, there was short interest...

MiNK Therapeutics, Inc. (NASDAQ:INKT) Short Interest Down 7.6% in February

MiNK Therapeutics announces first patient dosed in Phase 2 study for agenT-797

Dr. Yelena Janjigian, Chief of GI Cancers, Leads Investigator Sponsored Study at Memorial Sloan Kettering Cancer CenterTrial is Supported by Stand Up To Cancer as Part of an Initiative to Find...

First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK's Allogeneic INKT Cell Therapy and Agenus' Botensilimab and Balstilimab

MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of allogeneic invariant natural killer T cell therapies to treat cancer and other immune mediated diseases. The company was founded in 2017 and is headquartered in New York, NY.

Volume	29,534.00
52-Wk High	$3.34
52-Wk Low	$0.75

INKT MiNK Therapeutics Inc

About

Feed

News

Earnings

Fundamentals